Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Core Insights - Allogene Therapeutics is advancing its allogeneic CAR T therapy portfolio aimed at improving access to cell therapy for cancer and autoimmune diseases, with a focus on earlier treatment and broader application [1][2] Financial Performance - For Q3 2025, the company reported a net loss of $41.4 million, or $0.19 per share, with total operating expenses of $44.9 million [14][19] - As of September 30, 2025, Allogene had $277.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027 [10][21] Clinical Trials and Developments - The pivotal Phase 2 ALPHA3 trial with cema-cel is exploring allogeneic CAR T therapy for earlier-line treatment of large B-cell lymphoma (LBCL), with over 50 clinical sites active in the U.S. and Canada, and additional sites expected to open in Australia and South Korea in early 2026 [3][6] - The next milestone for the ALPHA3 trial is a futility analysis expected in the first half of 2026, focusing on minimal residual disease (MRD) conversion rates [4][6] - The Phase 1 RESOLUTION trial with ALLO-329 is investigating a dual CD19/CD70 CAR for autoimmune diseases, with a focus on reducing or eliminating lymphodepletion to improve tolerability [5][7] - ALLO-316 is the only allogeneic CAR T therapy showing significant response rates in metastatic solid tumors, with the TRAVERSE trial in renal cell carcinoma demonstrating early signs of efficacy [8][6] Strategic Vision - The company aims to shift from personalized therapies to off-the-shelf treatments that can be more widely available, enhancing consistency, safety, and quality in cell therapy [2][12] - Allogene's approach leverages ex vivo manufacturing to improve the precision and control of cell products before administration to patients [2][12]